NASDAQ:RLAY

Relay Therapeutics Competitors

$33.63

-1.72 (-4.87 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$33.33

Now: $33.63▼

$36.12

50-Day Range

$32.52

MA: $38.35▼

$44.02

52-Week Range

$31.31

Now: $33.63▼

$64.37

Volume844,000 shs

Average Volume781,312 shs

Market Capitalization$3.04 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Relay Therapeutics (NASDAQ:RLAY) Vs. QGEN, RGEN, NBIX, CRSP, XLRN, and FATE

Should you be buying RLAY stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Relay Therapeutics, including QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Acceleron Pharma (XLRN), and Fate Therapeutics (FATE).

Relay Therapeutics vs. QIAGEN Stock

Relay Therapeutics (NASDAQ:RLAY) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Relay Therapeutics and QIAGEN's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
QIAGEN	$1.53 billion	7.66	$-41,460,000.00	$1.43	35.87

Relay Therapeutics has higher earnings, but lower revenue than QIAGEN.

Profitability

This table compares Relay Therapeutics and QIAGEN's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	N/A	N/A
QIAGEN	11.18%	17.51%	8.44%

Institutional and Insider Ownership

98.4% of Relay Therapeutics shares are held by institutional investors. Comparatively, 43.6% of QIAGEN shares are held by institutional investors. 9.0% of QIAGEN shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Relay Therapeutics and QIAGEN, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	0	1	5	0	2.83
QIAGEN	0	5	9	0	2.64

Relay Therapeutics currently has a consensus price target of $57.40, suggesting a potential upside of 70.68%. QIAGEN has a consensus price target of $60.76, suggesting a potential upside of 18.46%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Relay Therapeutics is more favorable than QIAGEN.

Summary

QIAGEN beats Relay Therapeutics on 6 of the 9 factors compared between the two stocks.

Relay Therapeutics vs. Repligen Stock

Repligen (NASDAQ:RGEN) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Repligen and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$270.24 million	41.77	$21.41 million	$1.07	192.62
Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Repligen has higher revenue and earnings than Relay Therapeutics.

Profitability

This table compares Repligen and Relay Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Repligen	13.40%	6.58%	5.00%
Relay Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

84.3% of Repligen shares are held by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are held by institutional investors. 1.7% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Repligen and Relay Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0	0	5	0	3.00
Relay Therapeutics	0	1	5	0	2.83

Repligen currently has a consensus target price of $204.75, suggesting a potential downside of 0.66%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 70.68%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Repligen.

Summary

Repligen beats Relay Therapeutics on 6 of the 8 factors compared between the two stocks.

Relay Therapeutics vs. Neurocrine Biosciences Stock

Neurocrine Biosciences (NASDAQ:NBIX) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Neurocrine Biosciences and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$788.10 million	11.13	$37.01 million	$0.39	239.36
Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Neurocrine Biosciences has higher revenue and earnings than Relay Therapeutics.

Profitability

This table compares Neurocrine Biosciences and Relay Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	8.96%	18.18%	9.50%
Relay Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Neurocrine Biosciences and Relay Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0	8	12	0	2.60
Relay Therapeutics	0	1	5	0	2.83

Neurocrine Biosciences currently has a consensus target price of $129.2222, suggesting a potential upside of 38.43%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 70.68%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Neurocrine Biosciences.

Summary

Neurocrine Biosciences beats Relay Therapeutics on 6 of the 9 factors compared between the two stocks.

Relay Therapeutics vs. CRISPR Therapeutics Stock

CRISPR Therapeutics (NASDAQ:CRSP) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares CRISPR Therapeutics and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$289.59 million	30.15	$66.86 million	$1.17	98.92
Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

CRISPR Therapeutics has higher revenue and earnings than Relay Therapeutics.

Profitability

This table compares CRISPR Therapeutics and Relay Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-273.10%	-20.72%	-18.35%
Relay Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

66.4% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are held by institutional investors. 17.1% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for CRISPR Therapeutics and Relay Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2	4	12	0	2.56
Relay Therapeutics	0	1	5	0	2.83

CRISPR Therapeutics currently has a consensus target price of $158.80, suggesting a potential upside of 37.20%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 70.68%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than CRISPR Therapeutics.

Summary

Relay Therapeutics beats CRISPR Therapeutics on 6 of the 9 factors compared between the two stocks.

Relay Therapeutics vs. Acceleron Pharma Stock

Acceleron Pharma (NASDAQ:XLRN) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Analyst Recommendations

This is a summary of current ratings and target prices for Acceleron Pharma and Relay Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acceleron Pharma	0	3	10	1	2.86
Relay Therapeutics	0	1	5	0	2.83

Acceleron Pharma currently has a consensus target price of $148.2143, suggesting a potential upside of 16.84%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 70.68%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Acceleron Pharma.

Valuation & Earnings

This table compares Acceleron Pharma and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acceleron Pharma	$73.99 million	103.81	$-124,860,000.00	($2.38)	-53.30
Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Relay Therapeutics has lower revenue, but higher earnings than Acceleron Pharma.

Profitability

This table compares Acceleron Pharma and Relay Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acceleron Pharma	-157.84%	-31.62%	-28.11%
Relay Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

79.8% of Acceleron Pharma shares are held by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are held by institutional investors. 2.5% of Acceleron Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Relay Therapeutics vs. Fate Therapeutics Stock

Relay Therapeutics (NASDAQ:RLAY) and Fate Therapeutics (NASDAQ:FATE) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Relay Therapeutics and Fate Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	0	1	5	0	2.83
Fate Therapeutics	0	4	9	0	2.69

Relay Therapeutics presently has a consensus target price of $57.40, suggesting a potential upside of 70.68%. Fate Therapeutics has a consensus target price of $108.3125, suggesting a potential upside of 38.88%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Relay Therapeutics is more favorable than Fate Therapeutics.

Valuation and Earnings

This table compares Relay Therapeutics and Fate Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
Fate Therapeutics	$10.68 million	684.84	$-98,150,000.00	($1.44)	-54.16

Relay Therapeutics has higher earnings, but lower revenue than Fate Therapeutics.

Profitability

This table compares Relay Therapeutics and Fate Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	N/A	N/A
Fate Therapeutics	-810.13%	-35.51%	-25.40%

Institutional & Insider Ownership

98.4% of Relay Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are held by institutional investors. 21.4% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Relay Therapeutics beats Fate Therapeutics on 5 of the 9 factors compared between the two stocks.